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Abstract Because of the importance of biomarkers within
medicine as a whole and the increasing realisation that
imaging can safely provide biomarkers, the ESR executive
commissioned this report by experts in the field. It is hoped
that further awareness amongst our community will con-
tibute to further exploitation of the enormous wealth of
biomaker information available in our day to day imaging.
The all important issues surrounding validation and stand-
ardisation are discussed, together with proposals for a
European Network on Imaging Biomarkers to oversee such
aspects.
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Introduction
Biomarkers are characteristics that are objectively measured
as indicators of normal biological processes, pathological
changes, or pharmaceutical responses to a therapeutic
intervention [1]. Depending on the mode of collecting the
information, three types of biomarkers can be distinguished:
1. biochemical or histological parameters detected on
tissue samples obtained at biopsy or surgery,
2. biochemical parameters or cells obtained on blood or
urine samples,
3. anatomical, functional or molecular parameters
detected with imaging.
Biomarkers have multiple applications, including:
& Prediction: use as a tool to predict patients at risk of
disease. Calcium scoring as an indicator of the risk of
coronary artery disease is an example of predictive
biomarker.
& Detection: use as a diagnostic tool for the identification
of patients with disease. For example, measurement of
the hepatic perfusion index at CT has been proposed as
a biomarker for the detection of occult liver metastases
from colorectal cancer.
& Staging: use as a tool for classification of the extent of
disease. PET-CT with measurements of specific uptake
values (SUV) is increasingly used as staging biomarker
of various malignant tumors.
& Grading: use as an indicator of disease aggressiveness and
prognosis. Several studies with variable results have as-
sessed the correlation betweenMRI perfusion and diffusion
parameters and tumor aggressiveness or prognosis.
& Assessment of response to treatment: use as a tool for
evaluating the disease response to treatment.
Imaging biomarkers are useful for all these applications.
Compared with biochemical and histological biomarkers,
imaging biomarkers have the advantage of remaining non-
invasive and being spatially and temporally resolved.
Imaging biomarkers play an increasing role in major
medical areas such as cancer, cardiovascular diseases,
neurological and psychiatric diseases, musculoskeletal
diseases, metabolic diseases, and inflammatory and
autoimmunity-based diseases [2].
Drug development and imaging biomarkers
One area where imaging biomarkers have a critical role is
new drug development. Drug development has consider-




Insights Imaging (2010) 1:42–45
DOI 10.1007/s13244-010-0025-8
ably changed these last 20 years because impressive
progresses in molecular biology have been made, leading
to an increasingly detailed understanding of the genetic
abnormalities in diseases [3]. The discovery of gene
mutations and the identification of the cellular pathways
that their encoded proteins control provide a wide range of
new targets for drug development. Contemporary drug
development is an ordered process starting with identifica-
tion and validation of a target with high throughput
methodologies and going through lead identification and
optimization to preclinical and clinical trials of drug
candidates [4]. In preclinical trials, the efficacy and toxicity
of the drug is assessed in animals. Afterwards, the drug is
tested in patients during three clinical phases. In phase 1,
the toxicity, pharmacokinetics, pharmacodynamics, and
optimal dose levels are assessed; in phase 2, the biological
efficacy is determined; and in phase 3, controlled trials are
performed to assess the effects on clinical endpoints [5].
The term “pharmacokinetics” denotes what the body does
to the drug in terms of its absorption, distribution,
metabolism, and excretion, including the concentration-
time relationship and its dependence on dose, the term
“pharmacodynamics” denotes what the drug does to the
body [6].
Despite the successes with targeted drugs, there is a
general concern about the slow arrival and increasing cost
for development of new therapies. This is explained by the
fact that the most reliable way to assess the clinical impact
of a therapeutic intervention is through its effect on a
clinical endpoint such as survival or disease-free survival.
These standards may be impractical because long periods
are required for these clinical endpoints to be achieved and
trials with large number of patients are needed for their
evaluation. The developments in quantitative medical
imaging offer the opportunity of using imaging biomarkers
to speed up the drug development process. For example, the
lack of validated non-invasive biomarkers has been
recognized as a major hinder to the development and use
of antifibrotic drugs in patients with liver fibrosis [7].
Two types of biomarkers should be distinguished here:
& Pharmacodynamic biomarkers are used to show that
the drug has an anatomical, functional, or biological
effect on the target. Pharmacodynamic biomarkers are
used in preclinical studies and phase 1 trials to confirm
that the drug hits the target and that hitting this target
alters the pathophysiological mechanism. The use of
pharmacodynamic biomarkers in these early studies has
the potential to improve patient selection, accelerate the
drug development process, maximize the ability to
generate important information about human disease,
and decrease the risk of late and costly drug attrition
[8, 9].
& Surrogate endpoints are biomarkers that are intended to
substitute for a clinical endpoint and support approval
for marketing authorization. They should thus be used
in phase 2 and 3 trials to show that altering the
pathophysiological mechanism of the disease affects
the clinical status [10]. To substitute to a clinical
endpoint such as progression free or overall survival, a
surrogate endpoint has to be shown to be highly
correlated with the clinical endpoint in a series of
coordinated prospectively designed multi-centre trials
culminating in a formal meta-analysis [11].
Requirements for effective use of imaging biomarkers
In addition to technology stability (robustness), non-
invasiveness, and broad availability, there are two main
prerequisites for the effective use of imaging biomarkers,
which are standardization and validation.
Standardization
Standardization concerns the acquisition parameters for
imaging and the post-processing methods. It is an essential
step to ensure reproducibility across different centres and
machines. Several consensus conferences have been held
on standardization of perfusion MRI [12, 13] and diffusion
MRI [14]. As the imaging and quantification methods are
evolving, further update conferences are needed.
Validation
The sensitivity, specificity, precision, and reproducibility of
new biomarkers have to be rigorously tested [15]. The tests
should be conducted in phantoms, animals and humans [16].
The changes in biomarker values should be correlated to the
biological effect and clinical endpoints (qualification). The
validation requirements are much higher for surrogate
endpoints than for pharmacodynamic biomarkers. Qualifi-
cation as surrogate endpoints requires significant resources
and will, in many cases, only be possible in a concerted
effort of academia, industry and regulatory authorities, as
proposed for example by the Biomarkers Consortium (http://
www.biomarkersconsortium.org), a public-private partner-
ship managed by the Foundation for the National Institutes
of Health in the USA.
Types of biomarkers
Anatomical, functional and molecular characteristics can be
used as imaging biomarkers. In cancer treatment, CT (or
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MRI) measurements of changes of tumor volume are based
on the “Response evaluation Criteria in Solid Tumours”
(RECIST) criteria [17]. These anatomical biomarkers are
the only imaging surrogate endpoints that are accepted in
cancer treatment. However, these anatomical biomarkers
are suboptimal to assess the effect of some targeted
treatments that do not cause regression of tumor volume,
but rather increase in the extent of tumor necrosis [18].
A lot of functional biomarkers obtained with several
imaging methods, including PET, contrast-enhanced CT,
perfusion CT and MRI, diffusion-weighted MRI, MR
elastography and spectroscopy, have the potential to
complement or even replace the RECIST criteria. However,
important efforts of qualification and standardization
remain to be done before the acceptance of some of these
functional biomarkers as surrogate endpoints. 18F-FDG-
PET may serve as an illustrative example. In clinical
routine, 18F-FDG-PET is increasingly used to assess the
response to treatment in tumor patients. However, 18F-
FDG-PET as an imaging biomarker has not yet been
sufficiently validated to be accepted as a surrogate endpoint
for clinical studies by regulatory agencies. Currently, a
multi-centre qualification study of 18F-FDG-PET/CT as a
predictive marker of tumor response and patient outcome in
patients with non-small cell lung cancer has been initiated
by the American College of Radiology Imaging Network
(ACRIN).
Functional imaging biomarkers are increasingly used as
pharmacodynamic biomarkers. Relative to molecular imag-
ing biomarkers, which are target-specific, functional imag-
ing biomarkers have the advantage of being downstream
markers that probe general capabilities of disease, including
cell death, proliferation, glycolysis, hypoxia, tumor inva-
siveness, angiogenesis, inflammation and fibrosis. Al-
though a lot of functional imaging biomarkers have been
proposed as pharmacodynamic biomarkers in early drug
development, most of these biomarkers need further
validation and standardization for their qualification in
phase 1 and 2 human studies.
Proposed actions
The working group on imaging biomarkers recommends
the creation of a European Network on Imaging Biomarkers
(ENIB) under the umbrella of the European Institute for
Biomedical Imaging research (EIBIR) and the European
Society of Radiology (ESR) to coordinate, conduct and
stimulate research and education about the development,
standardization, validation, and qualification of imaging
biomarkers at the European level. Extensive and compre-
hensive research in this field is often beyond the means of
individual research groups and can best be accomplished
through the multidisciplinary, multinational efforts of
scientists. The cooperation of radiologists, nuclear medicine
specialists, clinicians, and basic scientists in physics,
biology, pathology, bioengineering, and mathematics is
needed. The main tasks of ENIB will be:
& To coordinate the development of new biomarkers,
especially biomarkers that probe hallmarks of diseases
such as cell death, proliferation, glycolysis, hypoxia, tumor
invasiveness, angiogenesis, inflammation and fibrosis.
& To provide standardization of the acquisition parameters
for imaging and of the quantitative post-processing
methods.
& To provide multi-centre validation and qualification of
pharmacodynamic imaging biomarkers and surrogate
endpoints.
& To stimulate comparative efficacy assessment between
imaging biomarkers and other biomarkers, including
histochemical and soluble biomarkers.
& To provide education about imaging biomarkers, in-
cluding the creation of research fellowships programs in
quantitative imaging and biomarkers.
The European Network on Imaging Biomarkers will
work in cooperation with industry (pharmaceutical and
medical device companies), European regulatory agencies
(EMEA) [19], and international medical societies, including
ECCO, EORTC, RSNA, EANM, ISMRM, ESMRMB and
the subspeciality societies of the ESR for biomarker
standardization, validation and qualification. The main
purpose of ENIB will be to boost at the European level
the development and use of qualified imaging biomarkers
that will help in diagnosis, treatment assessment and drug
development.
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